Melissa B. Epperly's most recent trade in Roivant Sciences Ltd was a trade of 543 Common Shares done . Disclosure was reported to the exchange on July 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2026 | 543 | 17,017 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.46 per share. | 29 Jun 2026 | 17,750 | 34,224 | - | 4.5 | 79,165 | Common Shares |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 17,750 | 169,166 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Sale of securities on an exchange or to another person at price $ 34.32 per share. | 29 Jun 2026 | 15,002 | 19,222 | - | 34.3 | 514,869 | Common Shares |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Sale of securities on an exchange or to another person at price $ 34.71 per share. | 29 Jun 2026 | 2,748 | 16,474 | - | 34.7 | 95,383 | Common Shares |
| Nautilus biotech Inc | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2026 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2026 | 670 | 16,474 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Sale of securities on an exchange or to another person at price $ 28.68 per share. | 16 Mar 2026 | 41,861 | 15,804 | - | 28.7 | 1,200,573 | Common Shares |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2026 | 815 | 57,719 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.98 per share. | 20 Jan 2026 | 54 | 57,665 | - | 23.0 | 1,241 | Common Shares |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2025 | 1,056 | 56,904 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2025 | 33,726 | 33,726 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2025 | 14,524 | 57,509 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Other type of transaction at price $ 13.77 per share. | 10 Sep 2025 | 1,661 | 55,848 | - | 13.8 | 22,872 | Common Shares |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2025 | 1,609 | 42,985 | - | 0 | Common Shares | |
| Nautilus biotech Inc | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2025 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2025 | 1,847 | 41,376 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 1,672 | 39,709 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. | 23 Jan 2025 | 180 | 39,529 | - | 11.2 | 2,018 | Common Shares |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2024 | 1,613 | 38,037 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Other type of transaction at price $ 12.12 per share. | 12 Sep 2024 | 4,245 | 36,424 | - | 12.1 | 51,449 | Common Shares |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 27,894 | 27,894 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 16,406 | 40,669 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2024 | 1,702 | 24,263 | - | 0 | Common Shares | |
| Nautilus biotech Inc | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2024 | 1,146 | 22,684 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.90 per share. | 24 Apr 2024 | 123 | 22,561 | - | 10.9 | 1,341 | Common Shares |
| Zentalis Pharma Inc | Melissa Epperly B. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.44 per share. | 12 Feb 2024 | 2,573 | 451,449 | - | 11.4 | 29,435 | Common Stock |
| Zentalis Pharma Inc | Epperly Melissa B. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 75,000 | 462,691 | - | 0 | Common Stock | |
| Zentalis Pharma Inc | Melissa Epperly B. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 01 Feb 2024 | 8,669 | 454,022 | - | 11.5 | 100,040 | Common Stock |
| Roivant Sciences Ltd | B. Melissa Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 1,207 | 21,538 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,280 | 1,280 | - | 0 | Common Shares | |
| Kinnate Biopharma Inc | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.98 per share. | 13 Feb 2023 | 5,227 | 392,048 | - | 20.0 | 104,411 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.42 per share. | 13 Feb 2023 | 2,624 | 397,275 | - | 20.4 | 53,594 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 148,043 | 148,043 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 101,957 | 399,899 | - | 0 | Common Stock | |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 50,000 | 297,543 | - | 0 | Common Stock | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 186,916 | 186,916 | - | - | Stock Option (Right to Buy) | |
| Nautilus biotech Inc | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 86,467 | 86,467 | - | - | Stock Option (Right to Buy) | |
| Kinnate Biopharma Inc | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 20,250 | 20,250 | - | - | Stock Option (right to buy) | |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.75 per share. | 04 Apr 2022 | 8,094 | 256,400 | - | 48.7 | 394,562 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 51.99 per share. | 04 Apr 2022 | 4,512 | 247,767 | - | 52.0 | 234,562 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.70 per share. | 04 Apr 2022 | 2,818 | 252,279 | - | 50.7 | 142,866 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.90 per share. | 04 Apr 2022 | 1,303 | 255,097 | - | 49.9 | 65,022 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 52.44 per share. | 04 Apr 2022 | 353 | 247,414 | - | 52.4 | 18,511 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.81 per share. | 23 Feb 2022 | 1,211 | 265,196 | - | 48.8 | 59,109 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.59 per share. | 23 Feb 2022 | 702 | 264,494 | - | 49.6 | 34,811 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 38,489 | 38,489 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 16,405 | 266,407 | - | 0 | Common Stock | |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.13 per share. | 02 Oct 2021 | 17,080 | 250,002 | - | 67.1 | 1,146,580 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 52.00 per share. | 18 Aug 2021 | 8,285 | 266,685 | - | 52.0 | 430,800 | Common Stock |
| Zentalis Pharma Inc | Melissa B. Epperly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 52.00 per share. | 18 Aug 2021 | 1,326 | 258,400 | - | 52.0 | 68,948 | Common Stock |